[Federal Register Volume 65, Number 79 (Monday, April 24, 2000)]
[Notices]
[Pages 21774-21775]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-10181]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting Richard U. 
Rodriguez, M.B.A., at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7056 ext. 287; fax: 301/402-
0220; e-mail: <a href="/cdn-cgi/l/email-protection#95e7e7a4a0a1efd5fbfcfdbbf2fae3"><span class="__cf_email__" data-cfemail="1567672420216f557b7c7d3b727a63">[email protected]</span></a>. A signed Confidential Disclosure 
Agreement will be required to receive copies of the patent 
applications.

Identification of a Novel Amplified Gene, MB1, at 17q23

Anne H Kallioniemi, Maarit T Barlund, Outi M Monni, Juha T Kononen, 
Olli P Kallioniemi (NHGRI)
DHHS Reference No. E-038-00/0 filed 13 Dec 1999

    DNA amplification at 17q23 is one of the most common genetic 
alterations in breast cancer. Genes affected by this amplification may 
have a critical role in

[[Page 21775]]

breast cancer development and progression and may provide targets for 
anti-cancer therapy. The inventors have identified a novel gene from 
the amplified region, named MB1, which has no homology to any known 
genes. MB1 is amplified in about 9% of primary breast tumors and is 
overexpressed in breast cancer cell lines with amplification. MB1 may 
define a critically important breast cancer gene which could have 
significance for development of improved diagnostics against breast 
cancer.

The Use of Recombinant Cholera Toxin-B for the Treatment of 
Inflammatory Bowel Disease

Warren Strober, Monica Boirivant, Ivan J Fuss, Brian L Kelsall (NIAID)
Serial No. 60/165,111 filed 12 Nov 1999

    The present invention provides methods of treating or preventing 
inflammation in a subject, comprising administering to the subject an 
effective amount of cholera toxin subunit B (CT-B). In particular, the 
present invention provides methods of decreasing the activity of 
interferon-gamma in a subject, decreasing the activity of IL-12 in a 
subject, and treating or preventing a Th1 T-cell mediated autoimmune 
disorder.

    Dated: April 18, 2000.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 00-10181 Filed 4-21-00; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>